JP2024091777A5 - - Google Patents
Info
- Publication number
- JP2024091777A5 JP2024091777A5 JP2024066552A JP2024066552A JP2024091777A5 JP 2024091777 A5 JP2024091777 A5 JP 2024091777A5 JP 2024066552 A JP2024066552 A JP 2024066552A JP 2024066552 A JP2024066552 A JP 2024066552A JP 2024091777 A5 JP2024091777 A5 JP 2024091777A5
- Authority
- JP
- Japan
- Prior art keywords
- human subject
- agent
- antibody
- tau
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| US63/273,216 | 2021-10-29 | ||
| JP2022172479A JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Division JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024091777A JP2024091777A (ja) | 2024-07-05 |
| JP2024091777A5 true JP2024091777A5 (https=) | 2025-11-04 |
Family
ID=84367272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2024066552A Pending JP2024091777A (ja) | 2021-10-29 | 2024-04-17 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2025005276A Pending JP2025063187A (ja) | 2021-10-29 | 2025-01-15 | インターロイキン－３４を標的とする化合物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005276A Pending JP2025063187A (ja) | 2021-10-29 | 2025-01-15 | インターロイキン－３４を標的とする化合物及び方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (https=) |
| EP (1) | EP4423127A1 (https=) |
| JP (3) | JP7622019B2 (https=) |
| KR (1) | KR20240099349A (https=) |
| CN (1) | CN118475610A (https=) |
| AR (1) | AR127484A1 (https=) |
| AU (1) | AU2022376940A1 (https=) |
| CA (1) | CA3236555A1 (https=) |
| CL (1) | CL2024001303A1 (https=) |
| CO (1) | CO2024005417A2 (https=) |
| CR (1) | CR20240170A (https=) |
| DO (1) | DOP2024000076A (https=) |
| EC (1) | ECSP24032906A (https=) |
| IL (1) | IL312380A (https=) |
| JO (1) | JOP20240103A1 (https=) |
| MX (1) | MX2024005153A (https=) |
| PE (1) | PE20241471A1 (https=) |
| TW (1) | TW202336034A (https=) |
| WO (1) | WO2023076995A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| PL3042917T3 (pl) | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| CN106573056A (zh) | 2014-07-28 | 2017-04-19 | 诺格尔制药有限公司 | 用于诊断和治疗炎症性肠病的方法和组合物 |
| ES2870983T3 (es) * | 2014-12-19 | 2021-10-28 | Univ Nantes | Anticuerpos anti-IL-34 |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| HK1249016A1 (zh) * | 2015-06-02 | 2018-10-26 | 豪夫迈‧罗氏有限公司 | 使用抗il-34抗体治疗神经疾病的组合物和方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CA3032692A1 (en) * | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
| KR102905634B1 (ko) | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
| TWI799840B (zh) * | 2020-04-30 | 2023-04-21 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
-
2022
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
- 2024-04-29 JO JOJO/P/2024/0103A patent/JOP20240103A1/ar unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022002524A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| JP2018535648A5 (https=) | ||
| CN112654640B (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| CA2400559A1 (en) | Humanized antibodies that sequester .alpha..beta. peptide | |
| JP2005501102A (ja) | 炎症性腸疾患の経口免疫グロブリン治療 | |
| JP2024091777A5 (https=) | ||
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| WO2022204244A1 (en) | Human ccl28 antibodies | |
| EP4232472A1 (en) | Method of safe administration of anti-tau antibody | |
| JP2025063187A5 (https=) | ||
| IL312380A (en) | Compounds and methods targeting interleukin-34 | |
| US20240109977A1 (en) | Anti-cd38 antibodies and their uses | |
| JP2024525870A (ja) | 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療 | |
| KR20240035835A (ko) | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 | |
| US20130004516A1 (en) | Drug for inflammatory bowel disease | |
| WO2024246085A1 (en) | Therapeutic use of bispecific anti-abeta/tfr antibodies | |
| TWI879859B (zh) | 急性期之視神經脊髓炎之預防或治療劑 | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| JP2023550672A5 (https=) | ||
| JP2024505195A5 (https=) | ||
| JP7789368B2 (ja) | 炎症性腸疾患に対する治療用抗体 | |
| TWI887333B (zh) | 失智症之預防或治療劑 | |
| US20240166733A1 (en) | A-fabp neutralizing monoclonal antibody and preparation method and use thereof | |
| WO2026060205A1 (en) | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |